There was a significant relationship between raised serum Creatinine and Tacrolimus Level (p = 0.03) irrespective of the cause of admission. The functional status of the graft at the end of one year in patients requiring admission was not significantly poor compared to the counterpart (p = 0.08). HAN SEUNG SEOK, KIM DONG KI, OH KOOK-HWAN, KIM YON SU Department of Internal Medicine, Seoul National University College MLN0128 chemical structure of Medicine, Seoul, Korea Introduction: Peritoneal dialysis after kidney transplant

failure is not referred, because the risk of infection may increase due to the use of immunosuppressive agents. However, the precise association between steroid use and the risk of peritonitis remains elusive. Methods: 41 patients undergoing peritoneal dialysis after graft loss (DAGL) were recruited. The patients were divided according to the tertiles of the mean steroid dose (mg) or the tapering steroid regimen.

DAPT The primary outcome such as the first episode of peritonitis was compared using Cox proportional hazard ratio (HR) analysis. Furthermore, the risk of peritonitis in the DAGL group was compared with that of 712 transplant-naïve (TN) patients. Results: The mean steroid doses were 0.3 mg, 2.3 mg, and 8.0 mg in the three tertiles. The 3rd tertile for the steroid dose had a greater risk of peritonitis than the 1st tertile (HR, 38.3 (3.9–376.7); P = 0.002). The tapering steroid regimen showed Lepirudin a significance as a predictive factor of peritonitis (HR, 6.0 (1.5–24.4); P = 0.013). The peritonitis risk of DAGL group was not different from that of TN group. However, the 3rd tertile for steroid dose had a greater HR than the TN group (HR, 3.0 (1.5–6.0); P = 0.001) [Figure]. The group with non-tapering steroid showed a slightly higher risk of peritonitis than the TN group: HR, 1.7 (0.9–3.0); P = 0.085. Conclusion: The present study firstly identified the association between steroid use and peritonitis risk in peritoneal dialysis patients with kidney transplant failure. Tapering steroid may be needed to reduce the risk of peritonitis in this patient group. MASUTANI KOSUKE1,3, TSUCHIMOTO AKIHIRO1, HARUYAMA NAOKI1, KITADA HIDEHISA2, OKABE

YASUHIRO2, TSURUYA KAZUHIKO3, KITAZONO TAKANARI1 1Department of Medicine and Clinical Science, Kyushu University; 2Department of Surgery and Oncology, Kyushu University; 3Department of Integrated Therapy for Chronic Kidney Disease Introduction: Once-daily extended-release tacrolimus (Tac-QD) has been shown to have equivalent efficacy and safety to the twice-daily formulation (Tac-BID) in kidney transplant patients. However, detailed comparison of allograft pathology found on a protocol biopsy (PB) in Tac-QD- versus Tac-BID-based regimens has not been described. Methods: We retrospectively investigated 119 de novo living-donor kidney transplant patients treated with Tac-QD (n = 90) or Tac-BID (n = 29) and their 3- and 12-month PB results.